ZaBeCor Pharmaceuticals is a biotechnology firm pioneering molecular advancements for asthma, allergies, and a spectrum of inflammatory and infectious diseases. Established in 1992 and based in Bala Cynwyd, Pennsylvania, the company is dedicated to the advancement of siRNA, antisense, and other molecular technologies for treating asthma, allergies, and various inflammatory and infectious diseases.
Their product lineup includes Excellair, aiming to combat asthma, allergy, ARDS, COPD, avian flu inflammation, uveitis, cystitis, rheumatoid arthritis, and other autoimmune and inflammatory illnesses. Additionally, they offer Recruitin Phagocytosis for infection through gene therapy, Disarmin Phagocytosis for autoimmune diseases using gene therapy, and Hematrol Steroid targeting low blood platelets, hemolytic anemia, rheumatoid arthritis, systemic lupus, ulcerative colitis, Crohn’s disease, psoriasis, and other steroid-responsive autoimmune conditions.
The company received a $50.00KVenture Round investment on 01 April 2009. With a focus on the health care and biotechnology industries, ZaBeCor Pharmaceuticals is poised to make significant strides in advancing treatments for a wide range of diseases and conditions through innovative molecular technologies.
